A new study analyzed blood samples from 11 patients with advanced-stage cancer. Researchers isolated circulating tumor cells (CTCs)—cancer cells that travel through the bloodstream—and performed detailed genomic analyses to investigate genetic alterations. After confirming that the isolated CTCs contained a sufficient proportion of tumor-derived cells, the team identified numerous patient-specific candidate “neoantigens” (tumor-specific markers).
This research explores the possibility of characterizing individual tumor features without collecting tumor tissue. It is not intended to directly guide clinical decisions or determine treatment plans. Details of the study are available in the PDF below.
The original English article is also available on the Frontiers in Immunology website.
